Altimmune, Inc. (DUS:3G0) Financings

Altimmune, Inc.

Financings

RaiseDate
Public offering of common stock and accompanying common stock warrants (or pre-funded warrants in lieu thereof)
Closed: US$225M raised · US$3 a share · Warrants at US$3 · Leerink Partners +2
Dealers: Leerink Partners (co-lead), Barclays (co-lead), Titan Partners (co-lead)
Buyers: Deep Track Capital (led the financing); TCGX; Viking Global Investors; RA Capital Management
Use of proceeds: Fund the upcoming Phase 3 trial in MASH, plus working capital and general corporate purposes
Apr 27, 2026
Registered direct offering of common stock (or pre-funded warrants in lieu thereof)
Closed: US$75M raised · Titan Partners, a division of American Capital Partners
Dealers: Titan Partners, a division of American Capital Partners (lead)
Buyers: new fundamental institutional investor (17,045,454 shares of common stock (or pre-funded warrants in lieu thereof))
Use of proceeds: Upcoming Phase 3 trial in MASH, working capital and general corporate purposes
Jan 29, 2026

Read by 6ix AI from the company's releases